A carregar...
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patien...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6477486/ https://ncbi.nlm.nih.gov/pubmed/31043947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000495782 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|